LONDON, UK, 4 March 2025 - In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumours (NETs), a ...
BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (Lantheus) today announced it has entered into multiple strategic agreements with Perspective Therapeutics, Inc.
[212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic ...
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results